Clinical Trial Update: A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 study evaluating eltrombopag in combination with a short course of dexamethasone for newly diagnosed immune thrombocy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Eltrombopag (eltrombopag)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Immune Thrombocytopenia (ITP) | Phase 2 | Status: COMPLETED | Results posted: 2025-03-17